Chronic lymphocytic leukaemia / Small Lymphocytic Lymphoma MedDRA version: 18.0 Level: LLT Classification code 10008976 Term: Chronic lymphocytic leukemia System Organ Class: 100000004864 MedDRA version: 18.0 Level: LLT Classification code 10041152 Term: Small lymphocytic lymphoma, consistent with CLL (Working Formulation) System Organ
Conditions
Interventions
Trade Name: Revlimid
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Lenalidomide
Concentration unit: mg milligram(s)
Concentrat
Sponsors
University of Liverpool
Royal Liverpool and Broadgreen University Hospital NHS Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • CLL/SLL requiring treatment by IWCLL 2008 criteria. At least one of the following criteria should be met: o Evidence of progressive marrow failure as manifested by the development of, or worsening of, anaemia and/or thrombocytopenia. o Massive (i.e. at least 6cm below the left costal margin) or progressive or symptomatic splenomegaly. o Massive (i.e. at least 10cm in longest diameter) or progressive or symptomatic lymphadenopathy. o Progressive lymphocytosis with an increase of more than 50% over a 2-month period or lymphocyte doubling time (LDT) of less than 6 months from a baseline value of at least 30x10^9/l and not due to causes other than CLL. o Constitutional symptoms defined as at least 10% unintentional weight loss within the previous 6 months, significant fatigue preventing usual activities, or fever of at least 38°C for at least 2 weeks or night sweats for at least one month in the absence of infection. • High risk CLL/SLL defined by at least one of the following criteria: o TP53 deletion or mutation affecting at least 20% of CLL cells o Resistant (SD/PD) to fludarabine-containing combination therapy o Relapse within 12 months of responding to fludarabine-containing combination therapy • No prior treatment with ofatumumab or lenalidomide • CLL not known to be resistant to glucocorticoids • No more than 3 previous treatment episodes for CLL • WHO performance status 0-2 • Aged at least 18 years • Written Informed Consent Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 0 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 0
Exclusion criteria
Exclusion criteria: • Neutrophil count less than 0.5x10^9/l or platelet count less than 25x10^9/l • Uncontrolled auto-immune haemolytic anaemia or thrombocytopenia • Total bilirubin >1.5 times upper normal limit (unless due to involvement of liver or a known history of Gilbert’s disease) or ALT >2.5 times upper normal limit (unless due to disease involvement of liver) • Active infection • Active gastritis or peptic ulcer disease • Uncontrolled diabetes mellitus or hypertension • History of recurrent thromboembolism • Seropositivity for HIV, HCV or HBV (surface antigen) • Renal impairment (eGFR less than 30ml/min) • Hepatic impairment (serum bilirubin more than twice the upper limit of normal unless due to Gilbert’s syndrome or CLL) • Concurrent treatment with glucocorticoids equivalent to more than prednisolone 20mg od • Presence or history of CNS disease (either CNS lymphoma or leukaemic meningitis) • History of Richter transformation • Concomitant malignancies except adequately treated localised non-melanoma skin cancers and other in-situ cancers, or invasive cancers that have been in remission for a period of time considered by the local investigator to pose a negligible risk of relapse during the period of the trial. • Major surgery within 28 days prior to registration • Any serious underlying medical or psychological conditions, which could impair the ability of the patient to participate in the trial or compromise ability to give informed consent • Treatment within a clinical trial within 30 days prior to trial entry • Adult patient under tutelage (not competent to sign informed consent) • Pregnant or lactating women • Patients unwilling or not able to adhere to the Lenalidomide Pregnancy Prevention Plan • Women taking the oral contraceptive pill within 4 weeks of study registration owing to an increased risk of thromboembolism • Women of childbearing potential, including women whose last menstrual period was less than 24 months prior to screening, unable or unwilling to use adequate contraception from study start to 28 days after the last dose of protocol therapy. Adequate contraception is defined as hormonal birth control, intrauterine device, double barrier method or total abstinence. Male subjects unable or unwilling to use adequate contraception methods from study start to one year after the last dose of protocol therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Complete Response (CR) rates for patients with high-risk CLL (Chronic Lymphocytic Leukaemia) remains an area where improved outcome is somewhat elusive. CLL210 is a study which hopes to improve the outcome of high-risk CLL patients by exploring whether the addition of a third drug called lenalidomide, and replacing alemtuzumab with another monoclonal antibody called ofatumumab to the regimen used in the CLL206 trial will improve patient outcome. The addition of lenalidomide to ofatumumab and dexamethasone, together with additional drugs to reduce side effects, hopes to answer two specific questions. These primary outcomes are: - INDUCTION QUESTION: CR\CRi and Tolerance rate after 6 months of induction therapy; tolerance is defined as absence of Grade 3+ infection and no treatment related death. ; Secondary Objective: Another change from the CLL206 trial is the replacement of a steroid called HDMP with a different steroid called dexamethasone. Again the intention is to reduce toxicities experienced by patients receiving the treatment. The secondary endpoints of the CLL210 trial are to assess: - Overall, complete and partial response rates following induction therapy - Minimal residual disease (MRD) negativity rate following induction therapy - Overall survival (time from start of study treatment to death) - Progression-free survival (time from initiation of study treatment to progression or death) - Time to treatment failure (time from initiation of study treatment to treatment failure defined as progression, death or initiation of alternative treatment due to failure to achieve CR or PR) - Duration of response (time from first achievement of CR or PR to first time of progression or death) - Toxicity - Quality of life - Descript | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): • Overall, complete and partial response rates following induction therapy • Minimal residual disease (MRD) negativity rate following induction therapy • Overall survival (time from start of study treatment to death) • Progression-free survival (time from initiation of study treatment to progression or death) • Time to treatment failure (time from initiation of study treatment to treatment failure defined as progression, death or initiation of alternative treatment due to failure to achieve CR or PR) • Duration of response (time from first achievement of CR or PR to first time of progression or death) • Toxicity • Quality of life • Descriptive summary of Progression-free and overall survival among transplant-eligible patients | — |
Countries
United Kingdom
Outcome results
None listed